Revitalizing pharmaceutical R&D: The value of real world evidence

Pharmaceutical companies face a major challenge that threatens reimbursement and value capture: The potential disruption from real world evidence (RWE) as a factor in evaluating new drugs. The emergence of health technology assessment practices today makes it still more difficult to achieve attractive reimbursement value for newly launched products.

Unknown PDF status